Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC

March 26th 2020

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

March 26th 2020

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

March 26th 2020

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

FLASCO Faculty Flesh Out Case Studies in GI Cancers

March 25th 2020

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Dr. Le on the Need for Aggressive Treatment Interventions in Oligometastatic CRC

March 25th 2020

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Dr. Raghav on Treatment Options in Newly Diagnosed mCRC

March 25th 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Dr. Overman on Second-Line Therapy Options for Colorectal Cancer

March 23rd 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Dr. Shah on the Role of Immunotherapy in Gastroesophageal Cancer

March 21st 2020

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Dr. Choti on the Benefits of Neoadjuvant Chemotherapy in Pancreatic Cancer

March 21st 2020

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Marshall on Challenges in CRC Treatment

March 21st 2020

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Dr. Mizrahi on the Goal of the COMMIT Trial in dMMR Metastatic CRC

March 20th 2020

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Olaparib Takes Key Regulatory Step Toward Japanese Approval in Pancreatic Cancer

March 19th 2020

Olaparib has received an orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer.

Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

March 19th 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Nivolumab/Ipilimumab Approval in Advanced HCC Calls for Nuanced Look at Available Data

March 16th 2020

Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.

Dr. Katz on Eligibility Criteria for Up-front Surgery in Pancreatic Cancer

March 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Dr. Putcha on the Utility of Blood-Based Assays in CRC

March 14th 2020

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Targeted Agents and Immunotherapy Revamp Treatment in HCC, While Biomarkers Remain Elusive

March 13th 2020

Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.

Dr. Pant on Exciting Data With PARP Inhibitors in Pancreatic Cancer

March 13th 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Dr. Armaghany on Gene Sequencing in CRC

March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Dr. Sapisochin on Determining Transplant Eligibility in HCC

March 13th 2020

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.